Applied Molecular Transport Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
13
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$9.5M
- Investors
-
1
Applied Molecular Transport General Information
Description
Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.
Contact Information
Website
www.appliedmt.comCorporate Office
- 325 Sharon Park Drive
- Suite 1001
- Menlo Park, CA 94025
- United States
Corporate Office
- 325 Sharon Park Drive
- Suite 1001
- Menlo Park, CA 94025
- United States
Applied Molecular Transport Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 27-Dec-2023 | $9.5M | Completed | Generating Revenue | ||
| 8. 2PO | 01-Apr-2021 | Completed | Generating Revenue | |||
| 7. IPO | 05-Jun-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 5. Later Stage VC (Series C) | 30-Sep-2019 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series B) | 10-Sep-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 23-Nov-2016 | Completed | Startup | |||
| 2. Accelerator/Incubator | 03-Mar-2015 | Completed | Startup | |||
| 1. Accelerator/Incubator | 10-Mar-2014 | Completed | Startup |
Applied Molecular Transport Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 5,157,213 | $0.000100 | $0.51 | $6.4 | $6.4 | 1x | $6.4 | 21.39% |
Applied Molecular Transport Comparisons
Industry
Financing
Details
Applied Molecular Transport Competitors (4)
One of Applied Molecular Transport’s 4 competitors is Adverum Biotechnologies, a Formerly VC-backed company based in Redwood City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Janssen Global Services | Venture Capital-Backed | Raritan, NJ |
Applied Molecular Transport Patents
Applied Molecular Transport Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3150859-A1 | Compositions, formulations, and interleukin production and purification | Pending | 16-Aug-2019 | ||
| CA-3151351-A1 | Compositions and particles for payload delivery | Pending | 16-Aug-2019 | ||
| AU-2020334967-A1 | Compositions and particles for payload delivery | Pending | 16-Aug-2019 | ||
| EP-3844169-A1 | Compositions, formulations, and interleukin production and purification | Pending | 16-Aug-2019 | ||
| AU-2020331939-A1 | Compositions, formulations, and interleukin production and purification | Pending | 16-Aug-2019 | C07K14/5428 |
Applied Molecular Transport Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Applied Molecular Transport Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BayBio FAST | Accelerator/Incubator | Minority | ||
| California Life Sciences | Accelerator/Incubator | |||
| EPIQ Capital Group | Family Office | Minority | ||
| Founders Fund | Venture Capital | Minority | ||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | Minority |
Applied Molecular Transport ESG
Risk Overview
Risk Rating
Updated October, 05, 2022
29.62 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile
Pharmaceuticals
Industry
of 1,008
Rank
Percentile
Biotechnology
Subindustry
of 465
Rank
Percentile
Applied Molecular Transport FAQs
-
When was Applied Molecular Transport founded?
Applied Molecular Transport was founded in 2010.
-
Where is Applied Molecular Transport headquartered?
Applied Molecular Transport is headquartered in Menlo Park, CA.
-
What is the size of Applied Molecular Transport?
Applied Molecular Transport has 13 total employees.
-
What industry is Applied Molecular Transport in?
Applied Molecular Transport’s primary industry is Biotechnology.
-
Is Applied Molecular Transport a private or public company?
Applied Molecular Transport is a Private company.
-
What is the current valuation of Applied Molecular Transport?
The current valuation of Applied Molecular Transport is .
-
What is Applied Molecular Transport’s current revenue?
The current revenue for Applied Molecular Transport is .
-
How much funding has Applied Molecular Transport raised over time?
Applied Molecular Transport has raised $358M.
-
Who are Applied Molecular Transport’s investors?
BayBio FAST, California Life Sciences, EPIQ Capital Group, Founders Fund, and Johnson & Johnson Innovation - JLABS are 5 of 8 investors who have invested in Applied Molecular Transport.
-
Who are Applied Molecular Transport’s competitors?
Adverum Biotechnologies, Merck & Co., Amgen, and Janssen Global Services are competitors of Applied Molecular Transport.
-
When was Applied Molecular Transport acquired?
Applied Molecular Transport was acquired on 27-Dec-2023.
-
Who acquired Applied Molecular Transport?
Applied Molecular Transport was acquired by Cyclo Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
